Roche receives request for additional information from the Federal Trade Commission
Roche announced today that it has received a request for additional information, often referred to as a ``second request,'' from the Federal Trade Commission in connection with Roche's proposed acquisition of Illumina, Inc..
Roche is set to strengthen its global leadership position in oncology and to expand in therapeutic areas such as metabolism, inflammation and diseases of the central nervous system.